The market size value per capita for Penicillins and Streptomycins in Switzerland demonstrated variability between 2013 and 2023. Starting at $7.83 in 2013, it peaked at $8.39 in 2016, before experiencing a decline, closing at $5.65 in 2023. The decline in value highlights a 6.73% decrease from 2022 to 2023 and a more pronounced contraction over the five-year period, reflected in a negative CAGR. The most significant drop occurred between 2016 and 2017, with a persistent downward trend in the following years.
Future trends may involve increasing substitution by newer drug classes or shifting healthcare policies. Additionally, ongoing medical advancements and antibiotic resistance challenges might influence market dynamics, potentially reversing the downward trajectory. Monitoring regulatory measures and innovations in antibiotics treatment is crucial.
| # | 31 Countries | US Dollars Per Capita | Last Year | |||
|---|---|---|---|---|---|---|
| 1 | 1 Italy | 11.76 | 2023 | View data | ||
| 2 | 2 New Zealand | 11.59 | 2023 | View data | ||
| 3 | 3 France | 11.21 | 2023 | View data | ||
| 4 | 4 Belgium | 11.17 | 2023 | View data | ||
| 5 | 5 United Kingdom | 10.77 | 2023 | View data | ||
| 7 | 7 Canada | 7.4 | 2023 | View data | ||
| 8 | 8 Germany | 5.7 | 2023 | View data | ||
| 9 | 9 Switzerland | 5.65 | 2023 | |||
| 10 | 10 Croatia | 5.57 | 2023 | View data | ||
| 11 | 11 Luxembourg | 5.24 | 2023 | View data | ||
